HEALTH OF WOMAN. 2018.2(128):118–129 

Wui-Jin Koh, MD; Nadeem R. Abu-Rustum, MD; Sarah Bean, MD; Kristin Bradley, MD; Susana M. Campos, MD, MPH, MS; Kathleen R. Cho, MD; Hye Sook Chon, MD; Christina Chu, MD; David Cohn, MD; Marta Ann Crispens, MD; Shari Damast, MD; Oliver Dorigo, MD, PhD; Patricia J. Eifel, MD; Christine M. Fisher, MD, MPH; Peter Frederick, MD; David K. Gaffney, MD, PhD; Suzanne George, MD; Ernest Han, MD, PhD; Susan Higgins, MD; Warner K. Huh, MD; John R. Lurain III, MD; Andrea Mariani, MD; David Mutch, MD; Christa Nagel, MD; Larissa Nekhlyudov, MD, MPH; Amanda Nickles Fader, MD; Steven W. Remmenga, MD; R. Kevin Reynolds, MD; Todd Tillmanns, MD; Stefanie Ueda, MD; Emily Wyse; Catheryn M. Yashar, MD; Nicole R. McMillian, MS; and Jillian L. Scavone, PhD

JNCN-Journal of the National Comprehensive Cancer Network | Volume16 Number2 | February 2018
These recommendations are also available on the Internet.
For the latest update, visit NCCN.org
Adapted – S.A. Shurpyak

REFERENCES

1. Siegel RL, Miller KD, Jemal A. 2017. Cancer Statistics, 2017. CA Cancer J Clin 67:7–30.

2. D’Angelo E, Prat J. 2010. Uterine sarcomas: a review. Gynecol Oncol 116:131–139.

3. Siegel RL, Miller KD, Jemal A. 2016. Cancer statistics, 2016. CA Cancer J Clin 66:7–30.

4. Van den Bosch T, Coosemans A, Morina M et al. 2012. Screening for uterine tumours. Best Pract Res Clin Obstet Gynaecol 26:257–266.

5. Kitchener HC, Trimble EL. 2009. Endometrial cancer state of the science meeting. Int J Gynecol Cancer 19:134–140.

6. Dinkelspiel HE, Wright JD, Lewin SN, Herzog TJ. 2013. Contemporary clinical management of endometrial cancer. Obstet Gynecol Int 2013:583891.

7. Obermair A, Youlden DR, Young JP et al. 2010. Risk of endometrial cancer for women diagnosed with HNPCC-related colorectal carcinoma. Int J Cancer 127:2678–2684.

8. Ueda SM, Kapp DS, Cheung MK et al. 2008. Trends in demographic and clinical characteristics in women diagnosed with corpus cancer and their potential impact on the increasing number of deaths. Am J Obstet Gynecol 198:218 e211–e216.

9. Chan JK, Sherman AE, Kapp DS et al. 2011. In uence of gynecologic oncologists on the survival of patients with endometrial cancer. J Clin Oncol 29:832–838.

10. Benedetti Panici P, Basile S, Salerno MG et al. 2014. Secondary analyses from a randomized clinical trial: age as the key prognostic factor in endometrial carcinoma. Am J Obstet Gynecol 210:363.e1–363.e10.

11. Doll KM, Tseng J, Denslow SA et al. 2014. High-grade endometrial cancer: revisiting the impact of tumor size and location on outcomes. Gynecol Oncol 132:44–49.

12. Resnick KE, Hampel H, Fishel R, Cohn DE. 2009. Current and emerging trends in Lynch syndrome identi cation in women with endometrial cancer. Gynecol Oncol 114:128–134.

13. Kwon JS, Scott JL, Gilks CB et al. 2011. Testing women with endometrial cancer to detect Lynch syndrome. J Clin Oncol 29:2247–2252.

14. Buchanan DD, Tan YY, Walsh MD et al. 2014. Tumor mismatch repair immunohistochemistry and DNA MLH1 methylation testing of patients with endometrial cancer diagnosed at age younger than 60 years optimizes triage for population-level germline mismatch repair gene mutation testing. J Clin Oncol 32:90–100.

15. Ferguson SE, Aronson M, Pollett A et al. 2014. Performance characteristics of screening strategies for Lynch syndrome in unselected women with newly diagnosed endometrial cancer who have undergone universal germline mutation testing. Cancer 120:3932–3939.

16. Goodfellow PJ, Billingsley CC, Lankes HA et al. 2015. Combined Microsatellite Instability, MLH1 Methylation Analysis, and Immunohistochemistry for Lynch Syndrome Screening in Endometrial Cancers From GOG210: An NRG Oncology and Gynecologic Oncology Group Study. J Clin Oncol 33:4301–4308.

17. Watkins JC, Yang EJ, Muto MG et al. 2017. Universal screening for mismatchrepair de ciency in endometrial cancers to identify patients with Lynch syndrome and Lynch-like syndrome. Int J Gynecol Pathol 36:115– 127.

18. Mills AM, Liou S, Ford JM et al. 2014. Lynch syndrome screening should be considered for all patients with newly diagnosed endometrial cancer. Am J Surg Pathol 38:1501–1509.

19. Smith RA, Cokkinides V, Brawley OW. 2012. Cancer screening in the United States, 2012: a review of current American Cancer Society guidelines and current issues in cancer screening. CA Cancer J Clin 62:129–142.

20. Crispens MA. 2012. Endometrial and ovarian cancer in lynch syndrome. Clin Colon Rectal Surg 25:97–102.

21. Manchanda R, Saridogan E, Abdelraheim A et al. 2012. Annual outpatient hysteroscopy and endometrial sampling (OHES) in HNPCC/Lynch syndrome (LS). Arch Gynecol Obstet 286:1555–1562.

22. Meyer LA, Broaddus RR, Lu KH. 2009. Endometrial cancer and Lynch syndrome: clinical and pathologic considerations. Cancer Control 16:14–22.

23. Jarvinen HJ, Renkonen-Sinisalo L, Aktan-Collan K et al. 2009. Ten years after mutation testing for Lynch syndrome: cancer incidence and outcome in mutation-positive and mutation-negative family members. J Clin Oncol 27:4793–4797.

24. Schmeler KM, Lynch HT, Chen LM et al. 2006. Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome. N Engl J Med 354:261–269.

25. McCluggage WG. 2006. My approach to the interpretation of endometrial biopsies and curettings. J Clin Pathol 59:801–812.

26. McKenney JK, Longacre TA. 2009. Low-grade endometrial adenocarcinoma: a diagnostic algorithm for distinguishing atypical endometrial hyperplasia and other benign (and malignant) mimics. Adv Anat Pathol 16:1–22.

27. Leitao MM, Jr., Kehoe S, Barakat RR et al. 2009. Comparison of D&C and of ce endometrial biopsy accuracy in patients with FIGO grade 1 endometrial adenocarcinoma. Gynecol Oncol 113:105–108.

28. Gimpelson RJ, Rappold HO. 1988. A comparative study between panoramic hysteroscopy with directed biopsies and dilatation and curettage. a review of 276 cases. Am J Obstet Gynecol 158:489–492.

29. Lee JH, Dubinsky T, Andreotti RF et al. 2011. ACR appropriateness criteria(R) pretreatment evaluation and follow-up of endometrial cancer of the uterus. Ultrasound Q 27:139–145.

30. Ortashi O, Jain S, Emannuel O et al. 2008. Evaluation of the sensitivity, speci city, positive and negative predictive values of preoperative magnetic resonance imaging for staging endometrial cancer. A prospective study of 100 cases at the Dorset Cancer Centre. Eur J Obstet Gynecol Reprod Biol 137:232–235.

31. Crivellaro C, Signorelli M, Guerra L et al. 2013. Tailoring systematic lymphadenectomy in high-risk clinical early stage endometrial cancer: the role of 18F-FDG PET/CT. Gynecol Oncol 130:306–311.

32. Kitajima K, Suzuki K, Senda M et al. 2011. Preoperative nodal staging of uterine cancer: is contrast-enhanced PET/CT more accurate than non-enhanced PET/CT or enhanced CT alone? Ann Nucl Med 25:511–519.

33. Antonsen SL, Jensen LN, Loft A et al. 2013. MRI, PET/CT and ultrasound in the preoperative staging of endometrial cancer – a multicenter prospective comparative study. Gynecol Oncol 128:300–308.

34. Bollineni VR, Ytre-Hauge S, Bollineni-Balabay O et al. 2016. High diagnostic value of 18F-FDG PET/CT in endometrial cancer: systematic review and meta-analysis of the literature. J Nucl Med 57:879–885.

35. Duk JM, Aalders JG, Fleuren GJ, de Bruijn HW. 1986. CA 125: a useful marker in endometrial carcinoma. Am J Obstet Gynecol 155:1097–1102.

36. Duk JM, Aalders JG, Fleuren GJ et al. 1989. Tumor markers CA 125, squamous cell carcinoma antigen, and carcinoembryonic antigen in patients with adenocarcinoma of the uterine cervix. Obstet Gynecol 73:661–668.

37. Patsner B, Orr JW, Jr., Mann WJ, Jr. 1990. Use of serum CA 125 measurement in posttreatment surveillance of early-stage endometrial carcinoma. Am J Obstet Gynecol 162:427–429.

38. Rose PG, Sommers RM, Reale FR et al. 1994. Serial serum CA 125 measurements for evaluation of recurrence in patients with endometrial carcinoma. Obstet Gynecol 84:12–16.

39. Price FV, Chambers SK, Carcangiu ML et al. 1998. CA 125 may not re ect disease status in patients with uterine serous carcinoma. Cancer 82:1720–1725.

40. Leslie KK, Thiel KW, Goodheart MJ et al. 2012. Endometrial cancer. Obstet Gynecol Clin North Am 39:255–268.

41. Smith RA, Brooks D, Cokkinides V et al. 2013. Cancer screening in the United States, 2013: a review of current American Cancer Society guidelines, current issues in cancer screening, and new guidance on cervical cancer screening and lung cancer screening. CA Cancer J Clin 63:88–105.

42. Boronow RC, Morrow CP, Creasman WT et al. 1984. Surgical staging in endometrial cancer: clinical-pathologic ndings of a prospective study. Obstet Gynecol 63:825–832.

43. Cowles TA, Magrina JF, Masterson BJ, Capen CV. 1985. Comparison of clinical and surgical-staging in patients with endometrial carcinoma. Obstet Gynecol 66:413–416.

44. Creasman WT, Morrow CP, Bundy BN et al. 1987. Surgical pathologic spread patterns of endometrial cancer. A Gynecologic Oncology Group Study. Cancer 60:2035–2041.

45. Benedet JL, Bender H, Jones H et al. 2000. FIGO staging classi cations and clinical practice guidelines in the management of gynecologic cancers. FIGO Committee on Gynecologic Oncology. Int J Gynaecol Obstet 70:209–262.

46. Wright JD, Barrena Medel NI, Sehouli J et al. 2012. Contemporary management of endometrial cancer. Lancet 379:1352–1360.

47. Pecorelli S. 2009. Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int J Gynaecol Obstet 105:103–104.

48. Creasman W. 2009. Revised FIGO staging for carcinoma of the endometrium. Int J Gynaecol Obstet 105:109.

49. Mariani A, Dowdy SC, Podratz KC. 2009. New surgical staging of endometrial cancer: 20 years later. Int J Gynaecol Obstet 105:110–111.

50. Amin MB, Edge SB, Greene FL et al. 2017. AJCC Cancer Staging Manual, 8th edition. New York: Springer.

51. Wethington SL, Barrena Medel NI, Wright JD, Herzog TJ. 2009. Prognostic signi cance and treatment implications of positive peritoneal cytology in endometrial adenocarcinoma: Unraveling a mystery. Gynecol Oncol 115:18–25.

52. Takeshima N, Nishida H, Tabata T et al. 2001. Positive peritoneal cytology in endometrial cancer: enhancement of other prognostic indicators. Gynecol Oncol 82:470–473.

53. Goff BA, Rice LW. 1990. Assessment of depth of myometrial invasion in endometrial adenocarcinoma. Gynecol Oncol 38:46–48.

54. Daniel AG, Peters WA, 3rd. 1988. Accuracy of of ce and operating room curettage in the grading of endometrial carcinoma. Obstet Gynecol 71:612–614.

55. Soliman PT, Frumovitz M, Spannuth W et al. 2010. Lymphadenectomy during endometrial cancer staging: practice patterns among gynecologic oncologists. Gynecol Oncol 119:291–294.

56. Kumar S, Mariani A, Bakkum-Gamez JN et al. 2013. Risk factors that mitigate the role of paraaortic lymphadenectomy in uterine endometrioid cancer. Gynecol Oncol 130:441–445.

57. Kilgore LC, Partridge EE, Alvarez RD et al. 1995. Adenocarcinoma of the endometrium: survival comparisons of patients with and without pelvic node sampling. Gynecol Oncol 56:29–33.

58. Havrilesky LJ, Cragun JM, Calingaert B et al. 2005. Resection of lymph node metastases in uences survival in stage IIIC endometrial cancer. Gynecol Oncol 99:689–695.

59. Todo Y, Kato H, Kaneuchi M et al. 2010. Survival effect of para-aortic lymphadenectomy in endometrial cancer (SEPAL study): a retrospective cohort analysis. Lancet 375:1165–1172.

60. Kitchener H, Swart AM, Qian Q et al. 2009. Ef cacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study. Lancet 373:125–136.

61. Benedetti Panici P, Basile S, Maneschi F et al. 2008. Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial. J Natl Cancer Inst 100:1707– 1716.

62. ACOG practice bulletin, clinical management guidelines for obstetrician- gynecologists, number 65, August 2005: management of endometrial cancer. Obstet Gynecol. 2005. 106:413–425.

63. Seamon LG, Fowler JM, Cohn DE. 2010. Lymphadenectomy for endometrial cancer: the controversy. Gynecol Oncol 117:6–8.

64. Creasman WT, Mutch DE, Herzog TJ. 2010. ASTEC lymphadenectomy and radiation therapy studies: are conclusions valid? Gynecol Oncol 116:293–294.

65. Uccella S, Podratz KC, Aletti GD, Mariani A. 2009. Lymphadenectomy in endometrial cancer. Lancet 373:1170; author reply 1170–1171.

66. Uccella S, Podratz KC, Aletti GD, Mariani A. 2009. Re: Systematic pelvic lymphadenectomy vs no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial. J Natl Cancer Inst 101:897–898; author reply 898–899.

67. Milam MR, Java J, Walker JL et al. 2012. Nodal metastasis risk in endometrioid endometrial cancer. Obstet Gynecol 119:286–292.

68. Neubauer NL, Lurain JR. 2011. The role of lymphadenectomy in surgical staging of endometrial cancer. Int J Surg Oncol 2011:814649.

69. Mariani A, Dowdy SC, Cliby WA et al. 2008. Prospective assessment of lymphatic dissemination in endometrial cancer: a paradigm shift in surgical staging. Gynecol Oncol 109:11–18.

70. Hirahatake K, Hareyama H, Sakuragi N et al. 1997. A clinical and pathologic study on para-aortic lymph node metastasis in endometrial carcinoma. J Surg Oncol 65:82–87.

71. Frederick PJ, Straughn JM, Jr. 2009. The role of comprehensive surgical staging in patients with endometrial cancer. Cancer Control 16:23–29.

72. Barlin JN, Khoury-Collado F, Kim CH et al. 2012. The importance of applying a sentinel lymph node mapping algorithm in endometrial cancer staging: beyond removal of blue nodes. Gynecol Oncol 125:531–535.

73. Ballester M, Koskas M, Coutant C et al. 2010. Does the use of the 2009 FIGO
classi cation of endometrial cancer impact on indications of the sentinel
node biopsy? BMC Cancer 10:465.

74. How J, Lau S, Press J et al. 2012. Accuracy of sentinel lymph node detection following intra-operative cervical injection for endometrial cancer: a prospective study. Gynecol Oncol 127:332–337.

75. Khoury-Collado F, Murray MP, Hensley ML et al. 2011. Sentinel lymph node mapping for endometrial cancer improves the detection of metastatic disease to regional lymph nodes. Gynecol Oncol 122:251–254.

76. Holloway RW, Abu-Rustum NR, Backes FJ et al. 2017. Sentinel lymph node mapping and staging in endometrial cancer: A Society of Gynecologic Oncology literature review with consensus recommendations. Gynecol Oncol 146:405–415.

77. Vidal F, Leguevaque P, Motton S et al. 2013. Evaluation of the sentinel lymph node algorithm with blue dye labeling for early-stage endometrial cancer in a multicentric setting. Int J Gynecol Cancer 23:1237–1243.

78. Kim CH, Khoury-Collado F, Barber EL et al. 2013. Sentinel lymph node mapping with pathologic ultrastaging: A valuable tool for assessing nodal metastasis in low-grade endometrial cancer with super cial myoinvasion. Gynecol Oncol.

79. Group SGOCPECW, Burke WM, Orr J et al. 2014. Endometrial cancer: a review and current management strategies: part I. Gynecol Oncol 134:385–392.

80. Soliman PT, Westin SN, Dioun S et al. 2017. A prospective validation study of sentinel lymph node mapping for high-risk endometrial cancer. Gynecol Oncol 146:234–239.

81. Abu-Rustum NR, Khoury-Collado F, Pandit-Taskar N et al. 2009. Sentinel lymph node mapping for grade 1 endometrial cancer: is it the answer to the surgical staging dilemma? Gynecol Oncol 113:163–169.

82. Ballester M, Dubernard G, Lecuru F et al. 2011. Detection rate and diagnostic accuracy of sentinel-node biopsy in early stage endometrial cancer: a prospective multicentre study (SENTI-ENDO). Lancet Oncol 12:469–476.

83. Press JZ, Gotlieb WH. 2012. Controversies in the treatment of early stage endometrial carcinoma. Obstet Gynecol Int 2012:578490.

84. Touhami O, Trinh XB, Gregoire J et al. 2015. Predictors of non-sentinel lymph node (non-SLN) metastasis in patients with sentinel lymph node (SLN) metastasis in endometrial cancer. Gynecol Oncol 138:41–45.

85. Rossi EC, Kowalski LD, Scalici J et al. 2017. A comparison of sentinel lymph node biopsy to lymphadenectomy for endometrial cancer staging (FIRES trial): a multicentre, prospective, cohort study. Lancet Oncol 18:384–392.

86. Paley PJ, Veljovich DS, Press JZ et al. 2016. A prospective investigation of uorescence imaging to detect sentinel lymph nodes at robotic-assisted endometrial cancer staging. Am J Obstet Gynecol 215:117 e111–117.

87. Sinno AK, Fader AN, Roche KL et al. 2014. A comparison of colorimetric versus uorometric sentinel lymph node mapping during robotic surgery for endometrial cancer. Gynecol Oncol 134:281–286.

88. Ruscito I, Gasparri ML, Braicu EI et al. 2016. Sentinel node mapping in cervical and endometrial cancer: indocyanine green versus other conventional dyes—a meta-analysis. Ann Surg Oncol 23:3749–3756.

89. Bodurtha Smith AJ, Fader AN, Tanner EJ. 2016. Sentinel lymph node assessment in endometrial cancer: a systematic review and meta-analysis. Am J Obstet Gynecol.

90. Cormier B, Rozenholc AT, Gotlieb W et al. 2015. Sentinel lymph node procedure in endometrial cancer: a systematic review and proposal for standardization of future research. Gynecol Oncol 138:478–485.

91. Naoura I, Canlorbe G, Bendifallah S et al. 2015. Relevance of sentinel lymph node procedure for patients with high-risk endometrial cancer. Gynecol Oncol 136:60–64.

92. Schiavone MB, Zivanovic O, Zhou Q et al. 2016. Survival of patients with uterine carcinosarcoma undergoing sentinel lymph node mapping. Ann Surg Oncol 23:196–202.

93. Holloway RW, Gupta S, Stavitzski NM et al. 2016. Sentinel lymph node mapping with staging lymphadenectomy for patients with endometrial cancer increases the detection of metastasis. Gynecol Oncol 141:206–210.

94. Darai E, Dubernard G, Bats AS et al. 2015. Sentinel node biopsy for the management of early stage endometrial cancer: long-term results of the SENTI-ENDO study. Gynecol Oncol 136:54–59.

95. Kim CH, Soslow RA, Park KJ et al. 2013. Pathologic ultrastaging improves micrometastasis detection in sentinel lymph nodes during endometrial cancer staging. Int J Gynecol Cancer 23:964–970.

96. Raimond E, Ballester M, Hudry D et al. 2014. Impact of sentinel lymph node biopsy on the therapeutic management of early-stage endometrial cancer: results of a retrospective multicenter study. Gynecol Oncol 133:506– 511.

97. Frimer M, Khoury-Collado F, Murray MP et al. 2010. Micrometastasis of endometrial cancer to sentinel lymph nodes: is it an artifact of uterine manipulation? Gynecol Oncol 119:496–499.

98. Touboul C, Bentivegna E, Uzan C et al. 2013. Sentinel lymph node in endometrial cancer: a review. Curr Oncol Rep 15:559–565.

99. Amezcua CA, MacDonald HR, Lum CA et al. 2006. Endometrial cancer patients have a signi cant risk of harboring isolated tumor cells in histologically negative lymph nodes. Int J Gynecol Cancer 16:1336–1341.

100. Todo Y, Kato H, Okamoto K et al. 2016. Isolated tumor cells and micrometastases in regional lymph nodes in FIGO stage I to II endometrial cancer. J Gynecol Oncol 27:e1.

101. Smerage JB, Barlow WE, Hortobagyi GN et al. 2014. Circulating tumor cells and response to chemotherapy in metastatic breast cancer: SWOG S0500. J Clin Oncol 32:3483–3489.

102. St Clair CM, Eriksson AG, Ducie JA et al. 2016. Low-volume lymph node metastasis discovered during sentinel lymph node mapping for endometrial carcinoma. Ann Surg Oncol 23:1653–1659.

103. Plante M, Stanleigh J, Renaud MC et al. 2017. Isolated tumor cells identi ed by sentinel lymph node mapping in endometrial cancer: does adjuvant treatment matter? Gynecol Oncol 146:240–246.

104. Scalici J, Laughlin BB, Finan MA et al. 2015. The trend towards minimally invasive surgery (MIS) for endometrial cancer: an ACS-NSQIP evaluation of surgical outcomes. Gynecol Oncol 136:512–515.

105. Janda M, Gebski V, Davies LC et al. 2017. Effect of total laparoscopic hysterectomy vs total abdominal hysterectomy on disease-free survival among women with stage I endometrial cancer: a randomized clinical trial. JAMA 317:1224–1233.

106. Fader AN, Weise RM, Sinno AK et al. 2016. Utilization of Minimally Invasive Surgery in Endometrial Cancer Care: A Quality and Cost Disparity. Obstet Gynecol 127:91–100.

107. Galaal K, Bryant A, Fisher AD et al. Laparoscopy versus laparotomy for the management of early stage endometrial cancer. Cochrane Database Syst Rev 2012:CD006655.

108. Kornblith AB, Huang HQ, Walker JL et al. 2009. Quality of life of patients with endometrial cancer undergoing laparoscopic international federation of gynecology and obstetrics staging compared with laparotomy: a Gynecologic Oncology Group study. J Clin Oncol 27:5337–5342.

109. Walker JL, Piedmonte MR, Spirtos NM et al. 2009. Laparoscopy compared with laparotomy for comprehensive surgical staging of uterine cancer: Gynecologic Oncology Group Study LAP2. J Clin Oncol 27:5331– 5336.

110. Mannschreck D, Matsuno RK, Moriarty JP et al. 2016. Disparities in surgical care among women with endometrial cancer. Obstet Gynecol 128:526–534.

111. Walker JL, Piedmonte MR, Spirtos NM et al. 2012. Recurrence and survival after random assignment to laparoscopy versus laparotomy for comprehensive surgical staging of uterine cancer: Gynecologic Oncology Group LAP2 Study. J Clin Oncol 30:695–700.

112. King LP, Miller DS. 2009. Recent progress: gynecologic oncology group trials in uterine corpus tumors. Rev Recent Clin Trials 4:70–74.

113. Vergote I, Amant F, Neven P. 2009. Is it safe to treat endometrial carcinoma endoscopically? J Clin Oncol 27:5305–5307.

114. Mourits MJ, Bijen CB, Arts HJ et al. 2010. Safety of laparoscopy versus laparotomy in early-stage endometrial cancer: a randomised trial. Lancet Oncol 11:763–771.

115. He H, Zeng D, Ou H et al. 2013. Laparoscopic treatment of endometrial cancer: systematic review. J Minim Invasive Gynecol 20:413–423.

116. Wang HL, Ren YF, Yang J et al. 2013. Total laparoscopic hysterectomy versus total abdominal hysterectomy for endometrial cancer: a meta-analysis. Asian Pac J Cancer Prev 14:2515–2519.

117. Mori KM, Neubauer NL. 2013. Minimally invasive surgery in gynecologic oncology. ISRN Obstet Gynecol 2013:312982.

118. Krill LS, Bristow RE. 2013. Robotic surgery: gynecologic oncology. Cancer J 19:167–176.

119. ElSahwi KS, Hooper C, De Leon MC et al. 2012. Comparison between 155 cases of robotic vs. 150 cases of open surgical staging for endometrial cancer. Gynecol Oncol 124:260–264.

120. Chan JK, Gardner AB, Taylor K et al. 2015. Robotic versus laparoscopic versus open surgery in morbidly obese endometrial cancer patients—a comparative analysis of total charges and complication rates. Gynecol Oncol 139:300–305.

121. Coronado PJ, Herraiz MA, Magrina JF et al. 2012. Comparison of perioperative outcomes and cost of robotic-assisted laparoscopy, laparoscopy and laparotomy for endometrial cancer. Eur J Obstet Gynecol Reprod Biol 165:289–294.

122. Seamon LG, Cohn DE, Henretta MS et al. 2009. Minimally invasive comprehensive surgical staging for endometrial cancer: Robotics or laparoscopy? Gynecol Oncol 113:36–41.

123. Bell MC, Torgerson J, Seshadri-Kreaden U et al. 2008. Comparison of outcomes and cost for endometrial cancer staging via traditional laparotomy, standard laparoscopy and robotic techniques. Gynecol Oncol 111:407–411.

124. Cardenas-Goicoechea J, Adams S, Bhat SB, Randall TC. 2010. Surgical outcomes of robotic-assisted surgical staging for endometrial cancer are equivalent to traditional laparoscopic staging at a minimally invasive surgical center. Gynecol Oncol 117:224–228.

125. Brudie LA, Backes FJ, Ahmad S et al. 2013. Analysis of disease recurrence and survival for women with uterine malignancies undergoing robotic surgery. Gynecol Oncol 128:309–315.

126. Backes FJ, Brudie LA, Farrell MR et al. 2012. Short- and long-term morbidity and outcomes after robotic surgery for comprehensive endometrial cancer staging. Gynecol Oncol 125:546–551.

127. Fleming ND, Ramirez PT. 2012. Robotic surgery in gynecologic oncology. Curr Opin Oncol 24:547–553.

128. Siesto G, Ornaghi S, Ieda N, Vitobello D. 2013. Robotic surgical staging for endometrial and cervical cancers in medically ill patients. Gynecol Oncol 129:593–597.

129. van Dam P, Hauspy J, Verkinderen L et al. 2011. Are costs of robot-assisted surgery warranted for gynecological procedures? Obstet Gynecol Int 2011:973830.

130. Weinberg L, Rao S, Escobar PF. 2011. Robotic surgery in gynecology: an updated systematic review. Obstet Gynecol Int 2011:852061.

131. Ramirez PT, Adams S, Boggess JF et al. 2012. Robotic-assisted surgery in gynecologic oncology: a Society of Gynecologic Oncology consensus statement. Developed by the Society of Gynecologic Oncology’s Clinical Practice Robotics Task Force. Gynecol Oncol 124:180–184.

132. AAGL. Guidelines for privileging for robotic-assisted gynecologic laparoscopy. J Minim Invasive Gynecol 2014. 21:157–167.

133. American Congress of Obstetricians and Gynecologists. Statement on Robotic Surgery by ACOG President James T. Breeden. 2013. Available at: http://www.acog.org/About-ACOG/News-Room/News-Releases/2013/ Statement-on-Robotic-Surgery. Accessed March 18. 2013.

134. Sinno AK, Fader AN. 2014. Robotic-assisted surgery in gynecologic oncology. Fertil Steril 102:922–932.

135. Gala RB, Margulies R, Steinberg A et al. 2014. Systematic review of robotic surgery in gynecology: robotic techniques compared with laparoscopy and laparotomy. J Minim Invasive Gynecol 21:353–361.

136. SGO Position Statement: Morcellation. Society of Gynecologic Oncology; 2013. Available at: https://www.sgo.org/newsroom/position-statements-2/ morcellation/. Accessed September 30. 2014.

137. Power Morcellation and Occult Malignancy in Gynecologic Surgery. The American College of Obstetrics and Gynecologists; 2014. Available at: http://www.acog.org/Resources-And-Publications/Task-Force-and- Work-Group-Reports/Power-Morcellation-and-Occult-Malignancy-in- Gynecologic-Surgery. Accessed September 30. 2014.

138. U.S. Department of Health and Human Services. FDA discourages use of laparoscopic power morcellation for removal of uterus or uterine broids Food and Drug Administration; 2014. Available at: http://www.fda.gov/ NewsEvents/Newsroom/PressAnnouncements/ucm393689.htm. Accessed 2014 September, 30.

139. Bogani G, Cliby WA, Aletti GD. 2015. Impact of morcellation on survival outcomes of patients with unexpected uterine leiomyosarcoma: a systematic review and meta-analysis. Gynecol Oncol 137:167–172.

140. Wright JD, Buck AM, Shah M et al. 2009. Safety of ovarian preservation in premenopausal women with endometrial cancer. J Clin Oncol 27:1214–1219.

141. Koskas M, Bendifallah S, Luton D et al. 2012. Safety of uterine and/or ovarian preservation in young women with grade 1 intramucous endometrial adenocarcinoma: a comparison of survival according to the extent of surgery. Fertil Steril 98:1229–1235.

142. Lee TS, Lee JY, Kim JW et al. 2013. Outcomes of ovarian preservation in a cohort of premenopausal women with early-stage endometrial cancer: A Korean Gynecologic Oncology Group study. Gynecol Oncol 131:289–293.

143. Manfredi R, Mirk P, Maresca G et al. 2004. Local-regional staging of endometrial carcinoma: role of MR imaging in surgical planning. Radiology 231:372–378.

144. Akin O, Mironov S, Pandit-Taskar N, Hann LE. 2007. Imaging of uterine cancer. Radiol Clin North Am 45:167–182.

145. Gunderson CC, Fader AN, Carson KA, Bristow RE. 2012. Oncologic and reproductive outcomes with progestin therapy in women with endometrial hyperplasia and grade 1 adenocarcinoma: a systematic review. Gynecol Oncol 125:477–482.

146. Baker J, Obermair A, Gebski V, Janda M. 2012. Ef cacy of oral or intrauterine device-delivered progestin in patients with complex endometrial hyperplasia with atypia or early endometrial adenocarcinoma: a meta-analysis and systematic review of the literature. Gynecol Oncol 125:263–270.

147. Gracia CR, Jeruss JS. 2013. Lives in the balance: women with cancer and the right to fertility care. J Clin Oncol 31:668–669.

148. Ushijima K, Yahata H, Yoshikawa H et al. 2007. Multicenter phase II study of fertility-sparing treatment with medroxyprogesterone acetate for endometrial carcinoma and atypical hyperplasia in young women. J Clin Oncol 25:2798–2803.

149. Hubbs JL, Saig RM, Abaid LN et al. 2013. Systemic and local hormone therapy for endometrial hyperplasia and early adenocarcinoma. Obstet Gynecol 121:1172–1180.

150. Trimble CL, Method M, Leitao M et al. 2012. Management of endometrial precancers. Obstet Gynecol 120:1160–1175.

151. Mehasseb MK, Latimer JA. 2012. Controversies in the management of endometrial carcinoma: an update. Obstet Gynecol Int 2012:676032.

152. Hahn HS, Yoon SG, Hong JS et al. 2009. Conservative treatment with progestin and pregnancy outcomes in endometrial cancer. Int J Gynecol Cancer 19:1068–1073.

153. Park JY, Kim DY, Kim JH et al. 2013. Long-term oncologic outcomes after fertility-sparing management using oral progestin for young women with endometrial cancer (KGOG 2002). Eur J Cancer 49:868–874.

154. Park JY, Seong SJ, Kim TJ et al. 2013. Pregnancy outcomes after fertility-sparing management in young women with early endometrial cancer. Obstet Gynecol 121:136–142.

155. Boente MP, Yordan EL, Jr., McIntosh DG et al. 1993. Prognostic factors and longterm survival in endometrial adenocarcinoma with cervical involvement. Gynecol Oncol 51:316–322.

156. Sartori E, Gadducci A, Landoni F et al. 2001. Clinical behavior of 203 stage II endometrial cancer cases: the impact of primary surgical approach and of adjuvant radiation therapy. Int J Gynecol Cancer 11:430–437.

157. Gadducci A, Cosio S, Genazzani AR. 2006. Old and new perspectives in the pharmacological treatment of advanced or recurrent endometrial cancer: hormonal therapy, chemotherapy and molecularly targeted therapies. Crit Rev Oncol Hematol 58:242–256.

158. Mountzios G, Pectasides D, Bournakis E et al. 2011. Developments in the systemic treatment of endometrial cancer. Crit Rev Oncol Hematol 79:278–292.

159. Fiorica JV, Brunetto VL, Hanjani P et al. 2004. Phase II trial of alternating courses of megestrol acetate and tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 92:10–14.

160. Altman AD, Thompson J, Nelson G et al. 2012. Use of aromatase inhibitors as first- and second-line medical therapy in patients with endometrial adenocarcinoma: a retrospective study. J Obstet Gynaecol Can 34:664–672.

161. Barker LC, Brand IR, Crawford SM. 2009. Sustained effect of the aromatase inhibitors anastrozole and letrozole on endometrial thickness in patients with endometrial hyperplasia and endometrial carcinoma. Curr Med Res Opin 25:1105–1109.

162. Rose PG, Brunetto VL, VanLe L et al. 2000. A phase II trial of anastrozole in advanced recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 78:212–216.

163. Decruze SB, Green JA. 2007. Hormone therapy in advanced and recurrent endometrial cancer: a systematic review. Int J Gynecol Cancer 17:964–978.

164. Fishman DA, Roberts KB, Chambers JT et al. 1996. Radiation therapy as exclusive treatment for medically inoperable patients with stage I and II endometrioid carcinoma with endometrium. Gynecol Oncol 61:189–196.

165. Coon D, Beriwal S, Heron DE et al. 2008. High-dose-rate Rotte “Y” applicator brachytherapy for de nitive treatment of medically inoperable endometrial cancer: 10-year results. Int J Radiat Oncol Biol Phys 71:779–783.

166. Niazi TM, Souhami L, Portelance L et al. 2005. Long-term results of high-dose- rate brachytherapy in the primary treatment of medically inoperable stage I-II endometrial carcinoma. Int J Radiat Oncol Biol Phys 63:1108–1113.

167. Van der Steen-Banasik E, Christiaens M, Shash E et al. 2016. Systemic review: radiation therapy alone in medical non-operable endometrial carcinoma. Eur J Cancer 65:172–181.

168. Creutzberg CL, van Stiphout RG, Nout RA et al. 2015. Nomograms for prediction of outcome with or without adjuvant radiation therapy for patients with endometrial cancer: a pooled analysis of PORTEC-1 and PORTEC-2 trials. Int J Radiat Oncol Biol Phys 91:530–539.

169. Group SGOCPECW, Burke WM, Orr J et al. 2014. Endometrial cancer: a review and current management strategies: part II. Gynecol Oncol 134:393–402.

170. Creutzberg CL, Nout RA. 2011. The role of radiotherapy in endometrial cancer: current evidence and trends. Curr Oncol Rep 13:472–478.

171. Klopp A, Smith BD, Alektiar K et al. 2014. The role of postoperative radiation therapy for endometrial cancer: executive summary of an American Society for Radiation Oncology evidence-based guideline. Pract Radiat Oncol 4:137–144.

172. Meyer LA, Bohlke K, Powell MA et al. 2015. Postoperative radiation therapy for endometrial cancer: American Society of Clinical Oncology clinical practice guideline endorsement of the American Society for Radiation Oncology evidence-based guideline. J Clin Oncol 33:2908–2913.

173. Morrow CP, Bundy BN, Kurman RJ et al. 1991. Relationship between surgical- pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: a Gynecologic Oncology Group study. Gynecol Oncol 40:55–65.

174. Neubauer NL, Havrilesky LJ, Calingaert B et al. 2009. The role of lymphadenectomy in the management of preoperative grade 1 endometrial carcinoma. Gynecol Oncol 112:511–516.

175. Gretz HFr, Economos K, Husain A et al. 1996. The practice of surgical staging and its impact on adjuvant treatment recommendations in patients with stage I endometrial carcinoma. Gynecol Oncol 61:409–415.

176. Ben-Shachar I, Pavelka J, Cohn DE et al. 2005. Surgical staging for patients presenting with grade 1 endometrial carcinoma. Obstet Gynecol 105:487–493.

177. Elshaikh MA, Al-Wahab Z, Mahdi H et al. 2015. Recurrence patterns and survival endpoints in women with stage II uterine endometrioid carcinoma: a multi-institution study. Gynecol Oncol 136:235–239.

178. Creutzberg CL, van Putten WL, Koper PC et al. 2000. Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma. Lancet 355:1404–1411.

179. Aalders J, Abeler V, Kolstad P, Onsrud M. 1980. Postoperative external irradiation and prognostic parameters in stage I endometrial carcinoma: clinical and histopathologic study of 540 patients. Obstet Gynecol 56:419–427.

180. Blake P, Swart AM, Orton J et al. 2009. Adjuvant external beam radiotherapy in the treatment of endometrial cancer (MRC ASTEC and NCIC CTG EN.5 randomised trials): pooled trial results, systematic review, and meta-analysis. Lancet 373:137–146.

181. Keys HM, Roberts JA, Brunetto VL et al. 2004. A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 92:744–751.

182. Creutzberg CL, van Putten WLJ, Wárlám-Rodenhuis CC et al. 2004. Outcome of high-risk stage IC, grade 3, compared with stage I endometrial carcinoma patients: the Postoperative Radiation Therapy in Endometrial Carcinoma Trial. J Clin Oncol 22:1234–1241.

183. Scholten AN, van Putten WLJ, Beerman H et al. 2005. Postoperative radiotherapy for stage 1 endometrial carcinoma: long-term outcome of the randomized PORTEC trial with central pathology review. Int J Radiat Oncol Biol Phys 63:834–838.

184. Hockel M, Dornhofer N. 2009. Treatment of early endometrial carcinoma: is less more? Lancet 373:97–99.

185. Creutzberg CL, Nout RA, Lybeert ML et al. 2011. Fifteen-year radiotherapy outcomes of the randomized PORTEC-1 trial for endometrial carcinoma. Int J Radiat Oncol Biol Phys 81:e631–638.

186. Alektiar KM, Venkatraman E, Chi DS, Barakat RR. 2005. Intravaginal brachytherapy alone for intermediate-risk endometrial cancer. Int J Radiat Oncol Biol Phys 62:111–117.

187. Nout RA, Smit VT, Putter H et al. 2010. Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high- intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial. Lancet 375:816–823.

188. Small W, Jr., Beriwal S, Demanes DJ et al. 2012. American Brachytherapy Society consensus guidelines for adjuvant vaginal cuff brachytherapy after hysterectomy. Brachytherapy 11:58–67.

189. Onsrud M, Cvancarova M, Hellebust TP et al. 2013. Long-term outcomes after pelvic radiation for early-stage endometrial cancer. J Clin Oncol 31:3951–3956.

190. Nout RA, Putter H, Jurgenliemk-Schulz IM et al. 2012. Five-year quality of life of endometrial cancer patients treated in the randomised Post Operative Radiation Therapy in Endometrial Cancer (PORTEC-2) trial and comparison with norm data. Eur J Cancer 48:1638–1648.

191. Roper B, Astner ST, Heydemann-Obradovic A et al. 2007. Ten-year data on 138 patients with endometrial carcinoma and postoperative vaginal brachytherapy alone: no need for external-beam radiotherapy in low and intermediate risk patients. Gynecol Oncol 107:541–548.

192. Nout RA, Putter H, Jurgenliemk-Schulz IM et al. 2009. Quality of life after pelvic radiotherapy or vaginal brachytherapy for endometrial cancer: rst results of the randomized PORTEC-2 trial. J Clin Oncol 27:3547–3556.

193. McCloskey SA, Tchabo NE, Malhotra HK et al. 2010. Adjuvant vaginal brachytherapy alone for high risk localized endometrial cancer as de ned by the three major randomized trials of adjuvant pelvic radiation. Gynecol Oncol 116:404–407.

194. Dunn EF, Geye H, Platta CS et al. 2014. Predictive factors of recurrence following adjuvant vaginal cuff brachytherapy alone for stage I endometrial cancer. Gynecol Oncol 133:494–498.

195. Randall ME, Filiaci V, McMeekin DS et al. 2017. A phase 3 trial of pelvic radiation therapy versus vaginal cuff brachytherapy followed by paclitaxel/ carboplatin chemotherapy in patients with high-risk, early-stage endometrial cancer: a Gynecology Oncology Group study [abstract]. Int J Radiat Oncol Biol Phys/

196. Chino JP, Jones E, Berchuck A et al. 2012. The in uence of radiation modality and lymph node dissection on survival in early-stage endometrial cancer. Int J Radiat Oncol Biol Phys 82:1872–1879.

197. Lee CM, Szabo A, Shrieve DC et al. 2006. Frequency and effect of adjuvant radiation therapy among women with stage I endometrial adenocarcinoma. JAMA 295:389–397.

198. Johnson N, Cornes P. 2007. Survival and recurrent disease after postoperative radiotherapy for early endometrial cancer: systematic review and metaanalysis. BJOG 114:1313–1320.

199. Kong A, Johnson N, Cornes P et al. 2007. Adjuvant radiotherapy for stage I endometrial cancer. Cochrane Database Syst Rev.

200. Kong A, Johnson N, Kitchener HC, Lawrie TA. 2012. Adjuvant radiotherapy for stage I endometrial cancer: an updated Cochrane systematic review and meta-analysis. J Natl Cancer Inst 104:1625–1634.

201. Eifel PJ. 2012. The role of adjuvant radiation therapy for stage I endometrial cancer: does meta-analysis reveal the answer? J Natl Cancer Inst 104:1615–1616.